Cargando…

Comparison of detection methods of EGFR T790M mutations using plasma, serum, and tumor tissue in EGFR-TKI-resistant non-small cell lung cancer

BACKGROUND: Osimertinib, a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor, exerts remarkable effects against EGFR T790M resistance mutation-positive non-small cell lung cancer. Identifying T790M mutation by re-biopsy is essential before prescribing osimertinib. Tissue bi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kobayashi, Keigo, Naoki, Katsuhiko, Manabe, Tadashi, Masuzawa, Keita, Hasegawa, Hanako, Yasuda, Hiroyuki, Kawada, Ichiro, Soejima, Kenzo, Betsuyaku, Tomoko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995408/ https://www.ncbi.nlm.nih.gov/pubmed/29922072 http://dx.doi.org/10.2147/OTT.S161745

Ejemplares similares

EGFR-mutant Non-small Cell Lung Cancer Accompanied by Transient Asymptomatic Pulmonary Opacities Successfully Treated with “Stop-And-Go” Osimertinib
por: Kobayashi, Keigo, et al.
Publicado: (2017)

Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations
por: Masuzawa, Keita, et al.
Publicado: (2017)

Non-small cell lung cancer PC-9 cells exhibit increased sensitivity to gemcitabine and vinorelbine upon acquiring resistance to EGFR-tyrosine kinase inhibitors
por: Hamamoto, Junko, et al.
Publicado: (2017)

In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer
por: Hirano, Toshiyuki, et al.
Publicado: (2015)

Secondary Brain Neoplasm after Stereotactic Radiosurgery in Patients with Metastatic Non-small Cell Lung Cancer
por: Nukaga, Shigenari, et al.
Publicado: (2018)

Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations
por: Ikemura, Shinnosuke, et al.
Publicado: (2019)

Combined therapy with EGFR TKI and gambogic acid for overcoming resistance in EGFR-T790M mutant lung cancer
por: WANG, CHENGDE, et al.
Publicado: (2015)

The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma
por: Zhang, Qiuyi, et al.
Publicado: (2016)

An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan
por: Wu, Shang-Gin, et al.
Publicado: (2020)

Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance
por: Zheng, D., et al.
Publicado: (2016)

Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients
por: Matsuo, Norikazu, et al.
Publicado: (2016)

The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy
por: Cheng, Wen-Chien, et al.
Publicado: (2021)

Quantification and Dynamic Monitoring of EGFR T790M in Plasma Cell-Free DNA by Digital PCR for Prognosis of EGFR-TKI Treatment in Advanced NSCLC
por: Wang, Zhijie, et al.
Publicado: (2014)

EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer
por: Sasada, Tetsuro, et al.
Publicado: (2013)

A case of EGFR mutation-positive lung adenocarcinoma in which the T790M allele fraction was increased by repeated EGFR-TKI treatment
por: Kimura, Hideharu, et al.
Publicado: (2019)

The Presence of EGFR T790M in TKI-Naïve Lung Cancer Samples of Patients Who Developed a T790M-Positive Relapse on First or Second Generation TKI Is Rare
por: Li, Weiting, et al.
Publicado: (2022)

Autophagosome-Mediated EGFR Down-Regulation Induced by the CK2 Inhibitor Enhances the Efficacy of EGFR-TKI on EGFR-Mutant Lung Cancer Cells with Resistance by T790M
por: So, Kwang Sup, et al.
Publicado: (2014)

A Case of Non-Small Cell Lung Cancer with Possible “Disease Flare” on Nivolumab Treatment
por: Chubachi, Shotaro, et al.
Publicado: (2016)

Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib
por: Tang, Kejing, et al.
Publicado: (2018)

The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC
por: Tamiya, Motohiro, et al.
Publicado: (2021)

The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M
por: Tseng, Jeng-Sen, et al.
Publicado: (2016)

Association between advanced NSCLC T790 M EGFR-TKI secondary resistance and prognosis: A observational study
por: Wang, Yuli, et al.
Publicado: (2018)

Expression of Concern: Autophagosome-Mediated EGFR Down-Regulation Induced by the CK2 Inhibitor Enhances the Efficacy of EGFR-TKI on EGFR-Mutant Lung Cancer Cells with Resistance by T790M
Publicado: (2019)

Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC
por: Imamura, Fumio, et al.
Publicado: (2020)

A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR‐TKI resistance
por: Wang, Wenxian, et al.
Publicado: (2016)

Association between EGFR gene mutant protein expression and T790M mutation after first-generation EGFR-TKI treatment resistance: a retrospective, single-arm clinical study
por: Zhang, Yiruo, et al.
Publicado: (2022)

Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury
por: Ohmori, Tohru, et al.
Publicado: (2021)

EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
por: Gu, Weiguang, et al.
Publicado: (2023)

Final report on plasma ctDNA T790M monitoring during EGFR-TKI treatment in patients with EGFR mutant non-small cell lung cancer (JP-CLEAR trial)
por: Naka, Go, et al.
Publicado: (2022)

Association of Tumor PD-L1 Expression with the T790M Mutation and Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Receiving EGFR-TKI Therapy
por: Inomata, Minehiko, et al.
Publicado: (2020)

Targeted Therapy-induced Facial Skin Toxicities: Impact on Quality of Life in Cancer Patients
por: Yagasaki, Kaori, et al.
Publicado: (2018)

Detection of plasma T790M mutation after the first generation EGFR-TKI resistance of non-small cell lung cancer in the real world
por: Li, Haiyan, et al.
Publicado: (2020)

EGFR/Met association regulates EGFR TKI resistance in breast cancer
por: Mueller, Kelly L, et al.
Publicado: (2010)

Deregulation of histone lysine methyltransferases contributes to oncogenic transformation of human bronchoepithelial cells
por: Watanabe, Hideo, et al.
Publicado: (2008)

Conventional real-time PCR-based detection of T790M using tumor tissue or blood in patients with EGFR TKI-resistant NSCLC
por: Wu, Ya-Lan, et al.
Publicado: (2017)

SH-1028, An Irreversible Third-Generation EGFR TKI, Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer
por: Han, Luwei, et al.
Publicado: (2021)

Intracellular levels of reactive oxygen species correlate with ABT‐263 sensitivity in non‐small‐cell lung cancer cells
por: Ohgino, Keiko, et al.
Publicado: (2020)

Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib
por: Oya, Yuko, et al.
Publicado: (2021)

Synergistic interaction between sorafenib and gemcitabine in EGFR-TKI-sensitive and EGFR-TKI-resistant human lung cancer cell lines
por: LI, JING, et al.
Publicado: (2013)

Multiple nodular lesions following Pneumocystis pneumonia in a non‐HIV immunocompromised patient
por: Asakura, Takanori, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_pv290jdtt3bp6gmbf19lnq9m3u